Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia
- 1 February 2008
- journal article
- case report
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (2) , 210-213
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by mucocutaneous and visceral telangiectasia. Hepatic involvement with vascular malformations may lead to portal hypertension, biliary ischemia, and high-output cardiac failure. Liver transplantation is indicated for life-threatening disease but carries significant risk from surgery and chronic immunosuppression. We report a case of a 47-year-old woman with HHT successfully treated with the vascular endothelial growth factor (VEGF) antibody bevacizumab. The patient was referred for consideration of liver transplantation because of hepatic HHT leading to high-output cardiac failure, diuretic resistant ascites, cholestasis, and malnutrition. As she was considered a high-risk candidate for transplantation, she underwent 6 courses of bevacizumab (5 mg/kg) over 12 weeks. A dramatic improvement in her clinical state was observed after 3 months with reversal of cholestasis, resolution of cardiac failure and ascites, and improvement in nutritional status with a 10% dry weight increase. Treatment induced a marked reduction in liver vascularity and halving of her liver volume from 4807 to 2269 mL over 6 months. This was associated with normalization of her cardiac output from 10.2 to 5.1 L/minute. Correspondingly, she ceased diuretic medications, returned to full-time work, and was delisted as a transplant candidate. She remains well 6 months after completing treatment. In conclusion, antagonism of VEGF receptors led to a dramatic regression of hepatic vascular malformations and reversal of high-output cardiac failure and complications of portal hypertension in this patient with HHT. Bevacizumab may potentially alleviate the need for liver transplantation in this group of patients. Liver Transpl 14:210–213. 2008. © 2008 AASLD.Keywords
This publication has 11 references indexed in Scilit:
- Pulmonary Vascular Manifestations of Hereditary Hemorrhagic Telangiectasia (Rendu-Osler Disease)Respiration, 2007
- Liver involvement in hereditary hemorrhagic telangiectasia (HHT)Journal of Hepatology, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Liver Transplantation for Hereditary Hemorrhagic TelangiectasiaAnnals of Surgery, 2006
- Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumabAnnals of Hematology, 2006
- Angiogenesis in life, disease and medicineNature, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Liver Disease in Patients with Hereditary Hemorrhagic TelangiectasiaNew England Journal of Medicine, 2000
- Angiogenesis in cancer and other diseasesNature, 2000